🇺🇸 FDA
Pipeline program

ALN-SOD

ALN-SOD-ALS-2351

Phase 2 small_molecule active

Quick answer

ALN-SOD for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials